QUOTE AND NEWS
FiercePharma  Nov 21  Comment 
In August, Sanofi's Genzyme won the FDA's blessing to take brand-new orphan drug Cerdelga into the U.S. Gaucher disease market, where the company hoped the pill could show up older, intravenous treatments. And now, it could be on its way to the...
SeekingAlpha  Nov 20  Comment 
Motley Fool  Nov 20  Comment 
Shares of healthcare giants GlaxoSmithKline and Sanofi have fallen hard this year, resulting in unusually high dividend yields for these two companies. Here is a look at which company offers the better opportunity for income investors moving forward.
FierceBiotech  Nov 20  Comment 
Investors shouldn't expect any major change in the R&D game plan set up by the recently departed CEO Chris Viehbacher. Sanofi says it will stay committed to Viehbacher's "open innovation" strategy, relying heavily on partners like Regeneron to...
Financial Times  Nov 20  Comment 
French drugmaker predicts surge in drug launches, including first dengue fever vaccine
Wall Street Journal  Nov 20  Comment 
French pharmaceutical giant Sanofi said it expects to launch 18 new drugs by 2020 that could boost sales by up to €30 billion ($37.6 billion) over five years.
FierceBiotech  Nov 19  Comment 
Sanofi is putting together a short list of candidates to see who will take Chris Viehbacher's place as the next CEO, and not surprisingly there's a distinct French accent to the names being bounced around just now.
newratings.com  Nov 19  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNYNF, SNY) reported new positive results from six Phase 3 ODYSSEY trials, showing that alirocumab significantly reduced low-density lipoprotein cholesterol or LDL-C, or "bad"...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki